Tetraphase Pharmaceuticals’ Stock Surges Amid Planned Merger With Melinta Therapeutics

Short-term focused gaining NASDAQ: TTPH was traded at $2.13 on Thursday. A couple of hours ago, there was an announcement that Melinta Therapeutics will acquire Tetraphase Pharmaceuticals completely before ending of Q3 2020. That news made TTPH grow by 47% at pre-market 8:17 AM EDT.

Recently announced Q1 2020 financial results revealed rising revenue quarterly and year over prior to that period. However, the cost of revenue slightly rose, still making the gross profit positive. The operating income, unfortunately, has always been written with the ‘minus’ sign.

Q1 2020 total equity gained $4.2 million while its market capitalization is overvalued at $15.471 million. However, 12 month based EPS stays negative at $29.7020.

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life